Understanding JAK Inhibitor Treatment Strategies for Patients with Myeloproliferative Neoplasms
Time: 11:00 am
day: Day One
Details:
- Rationale for JAK inhibition in MPN
- Success and limitations of JAK inhibitors in MPN
- Modern JAK inhibitor-based combination therapy approaches
Speakers:
Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr.…Read more